뇌종양 진단 시장 : 제품별, 종양 유형별, 검체 유형별, 종양 악성도별, 임상 용도별, 최종 사용자별 예측(2026-2032년)

The Brain Cancer Diagnostics Market is projected to grow by USD 4.03 billion at a CAGR of 10.62% by 2032.

Brain Cancer Diagnostics Executive Summary

Brain cancer diagnostics is moving from a primarily anatomy-based discipline to an integrated diagnostic model combining MRI, histopathology, immunohistochemistry, molecular pathology, next-generation sequencing, and increasingly liquid biopsy research. The World Health Organization's CNS tumor classification emphasizes molecular features such as IDH mutation status, 1p/19q codeletion, H3 K27 alteration, TERT promoter mutation, ATRX loss, and MGMT promoter methylation, making precision diagnostics central to treatment selection, prognosis, and clinical trial eligibility.

The clinical need is substantial. GLOBOCAN 2022 estimates about 322,000 new brain and central nervous system cancer cases and approximately 248,000 deaths worldwide, underscoring the urgency for earlier detection, accurate tumor grading, and faster molecular turnaround. For hospitals, diagnostic laboratories, imaging centers, and technology vendors, the brain cancer diagnostics landscape is increasingly defined by workflow integration, evidence-based biomarker testing, quality-assured imaging, and multidisciplinary tumor-board adoption.

Transformative Shifts in the Diagnostic Landscape

The brain cancer diagnostics landscape is being reshaped by three connected shifts: molecular classification, digital workflow adoption, and demand for minimally invasive monitoring. Conventional MRI remains foundational for detection, surgical planning, and treatment response assessment, but advanced MRI techniques, amino-acid PET in selected settings, perfusion imaging, spectroscopy, and integrated radiology-pathology review are improving diagnostic confidence.

Pathology is also changing. The WHO framework has made molecular testing indispensable rather than optional, particularly for adult diffuse gliomas and pediatric high-grade gliomas. This shift is increasing demand for validated NGS panels, methylation profiling in complex cases, robust tissue stewardship, and standardized reporting aligned with clinical guidelines. At the same time, cerebrospinal fluid and plasma-based liquid biopsy approaches are gaining research momentum for tumors where tissue access is limited, although clinical deployment still depends on analytical validation, regulatory acceptance, and demonstrated patient benefit.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across imaging triage, segmentation, radiomics, pathology image analysis, molecular prediction, and clinical decision support. AI tools can support reproducible tumor volume measurement, identify subtle imaging patterns, assist treatment response evaluation, and reduce repetitive manual workload; however, clinical value depends on external validation, explainability, bias monitoring, and integration with radiologist and pathologist workflows.

In brain cancer diagnostics, AI is most credible when positioned as an assistive layer rather than an autonomous substitute for expert interpretation. Data-backed implementation requires diverse training datasets, prospective performance monitoring, cybersecurity controls, and governance under medical device regulations. Organizations that combine AI with standardized MRI protocols, structured pathology data, and genomic results are better positioned to improve turnaround time, multidisciplinary coordination, biomarker interpretation, and eligibility screening for targeted therapies and clinical trials.

Key Regional Insights

North America remains a leading region for brain cancer diagnostics because of high MRI availability, broad adoption of molecular pathology, strong academic cancer centers, and established reimbursement pathways for clinically justified genomic testing. The United States and Canada benefit from active clinical trial networks, neuro-oncology subspecialization, and guideline-driven oncology care, although rural access, insurance complexity, and out-of-pocket costs continue to affect diagnostic equity.

Europe is shaped by centralized cancer networks, national health technology assessment, and the European Union's regulatory emphasis on in vitro diagnostic performance, medical device oversight, and data protection. Asia-Pacific combines world-class diagnostic capacity in Japan, South Korea, Australia, China's major urban centers, and Singapore with uneven access across lower-resource settings; rising neuro-oncology investment, expanding sequencing infrastructure, and digital imaging adoption are key growth drivers. Latin America is seeing increasing demand for MRI, pathology modernization, and referral-based molecular testing, led by larger urban health systems in Brazil and Mexico, while affordability and public-sector capacity remain persistent barriers. The Middle East is advancing through tertiary care investment, national cancer strategies, and international care partnerships, particularly in GCC health systems. Africa faces the greatest infrastructure constraints, including limited MRI availability, shortages of neuropathology specialists, and delayed diagnosis, yet regional referral centers and telepathology initiatives are gradually improving access to brain cancer diagnostics.

Key Group Insights

Across the G7, brain cancer diagnostics adoption is supported by mature imaging infrastructure, specialist neuro-oncology centers, recognized clinical guidelines, and reimbursement systems that increasingly treat molecular markers as clinically necessary. NATO countries overlap with many high-income health systems, supporting cross-border research collaboration, cybersecurity requirements for health data, and harmonized procurement standards for advanced diagnostic platforms.

The European Union is influential through regulatory frameworks for medical devices, in vitro diagnostics, and health data governance, creating higher evidence thresholds for diagnostic innovators while encouraging standardized quality systems. BRICS countries are strategically important because China, India, and Brazil combine large patient populations with expanding genomics and hospital investments, while Russia and South Africa contribute regional referral capacity and specialist expertise. ASEAN markets vary widely, with Singapore and Malaysia advancing precision oncology and digital pathology adoption, while other member states continue prioritizing MRI access, neuropathology training, and affordable molecular testing. GCC countries are investing in tertiary care, medical tourism, oncology centers, and national cancer strategies that favor advanced imaging, reference laboratory partnerships, and molecular testing adoption.

Key Country Insights

The United States anchors innovation through comprehensive cancer centers, regulated diagnostics, broad clinical trial activity, and high use of MRI and molecular profiling. Canada emphasizes publicly funded care, regional cancer programs, and quality-assured pathology networks, while Mexico and Brazil are expanding oncology infrastructure but face access disparities between private and public systems. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine guideline-based care with national reimbursement review, established neuro-oncology services, and increasing use of molecular classification, while Russia maintains strong urban specialist centers amid regional variation in access.

China is scaling hospital-based sequencing, AI imaging research, and tertiary neuro-oncology services, particularly in major metropolitan hospitals; India is growing rapidly in private diagnostics and oncology networks while addressing affordability, specialist distribution, and geographic access. Japan and South Korea offer advanced imaging, pathology quality, and digital health capacity, supported by aging populations, clinical research activity, and strong medical technology ecosystems. Australia benefits from integrated cancer registries, clinical trial participation, high-standard pathology networks, and advanced imaging access, making it an important precision neuro-oncology market with strong alignment to evidence-based diagnostics.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated, workflow-ready diagnostic solutions rather than standalone technologies. The strongest opportunities are in integrated platforms that connect MRI, pathology, genomic testing, methylation analysis, structured reporting, and tumor-board decision support while reducing turnaround time and preserving tissue for essential assays.

Vendors and providers should invest in evidence generation, including multi-center validation, analytical performance studies, health economic analysis, and real-world performance monitoring. Partnerships with academic hospitals, reference laboratories, clinical trial networks, and patient advocacy groups can accelerate adoption. Leaders should also design for interoperability, cybersecurity, regulatory compliance, and equitable access, because payers and health systems increasingly expect measurable clinical utility, reproducibility, and operational value, not only technical performance.

Research Methodology

This executive summary is developed from publicly available and verifiable sources, including WHO CNS tumor classification principles, IARC/GLOBOCAN cancer burden estimates, national cancer institute materials, peer-reviewed neuro-oncology literature, regulatory guidance, and recognized clinical practice guidelines. The analysis emphasizes diagnostic technologies with established or emerging clinical relevance, including MRI, histopathology, immunohistochemistry, molecular profiling, NGS, methylation analysis, digital pathology, AI-enabled imaging support, and liquid biopsy research.

The methodology uses triangulation across epidemiology, clinical guidelines, technology adoption patterns, regulatory considerations, regional healthcare infrastructure, and documented clinical workflow requirements. Insights are presented qualitatively where reliable comparable market figures are not publicly standardized, avoiding unsupported numerical claims. The focus is on evidence-backed strategic implications for stakeholders operating in brain cancer diagnostics.

Conclusion

Brain cancer diagnostics is entering a precision-driven phase where accurate classification, molecular confirmation, and rapid multidisciplinary interpretation directly influence therapy selection, trial eligibility, and patient counseling. The burden of CNS cancers and the complexity of glioma biology make diagnostic quality a strategic priority for health systems, laboratories, imaging providers, and technology developers.

Sustainable progress will depend on validated biomarkers, scalable molecular testing, AI-enabled workflow efficiency, regulatory-grade evidence, and equitable access to advanced imaging and pathology. Organizations that combine scientific rigor with practical implementation will be best positioned to lead in the evolving brain cancer diagnostics market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
    • 4.3.1.1. Molecular Classification Is Expanding the Diagnostic Revenue Pool
    • 4.3.1.2. Advanced Imaging and Quantification Are Raising Clinical Confidence
    • 4.3.1.3. Recurring Monitoring Needs Are Turning Diagnostics Into Longitudinal Care Infrastructure
    • 4.3.1.4. Workforce Constraints Are Accelerating Automation and Outsourced Expertise
  • 4.3.2. Key Restraints
    • 4.3.2.1. Capital Intensity and Reimbursement Variability Limit Broad Adoption
    • 4.3.2.2. Regulatory Complexity Raises the Cost and Time to Commercialization
  • 4.3.3. Key Opportunities
    • 4.3.3.1. Commercializing Biofluid-Based Monitoring for Less Invasive Disease Tracking
    • 4.3.3.2. Building Multimodal Diagnostic Orchestration Platforms
    • 4.3.3.3. Scaling Regional Neuro-Oncology Diagnostic Networks
  • 4.3.4. Key Challenges
    • 4.3.4.1. Solving Fragmented Data Infrastructure Before AI Can Scale Reliably
    • 4.3.4.2. Managing Geopolitical Supply Risk Across Imaging, Reagents, and Digital Infrastructure
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Cancer Diagnostics Market, by Offering

• 7.1. Instruments
  • 7.1.1. Imaging Instruments
    • 7.1.1.1. Magnetic Resonance Imaging (MRI) Systems
    • 7.1.1.2. Computed Tomography (CT) Scan Systems
    • 7.1.1.3. Positron Emission Tomography (PET) Systems
  • 7.1.2. Molecular & Pathology Instruments
    • 7.1.2.1. Sequencers
    • 7.1.2.2. Polymerase Chain Reaction (PCR) Systems
    • 7.1.2.3. Microarray Systems
    • 7.1.2.4. Fluorescence In Situ Hybridization (FISH) Platforms
    • 7.1.2.5. Next-Generation Sequencing (NGS) Systems
  • 7.1.3. Tissue Acquisition Instruments
    • 7.1.3.1. Biopsy Needles
    • 7.1.3.2. Stereotactic Frames
    • 7.1.3.3. Neuronavigation Systems
    • 7.1.3.4. Endoscopic Sampling Devices
• 7.2. Consumables & Reagents
  • 7.2.1. Imaging Consumables
    • 7.2.1.1. Contrast Agents
    • 7.2.1.2. Radiotracers
    • 7.2.1.3. Calibration Phantoms
  • 7.2.2. Molecular Reagents
    • 7.2.2.1. Sample Preparation Kits
    • 7.2.2.2. Extraction Kits
    • 7.2.2.3. Library Preparation Kits
    • 7.2.2.4. Sequencing Reagents
  • 7.2.3. Pathology Consumables
    • 7.2.3.1. Antibodies
    • 7.2.3.2. Probes
    • 7.2.3.3. Stains
    • 7.2.3.4. Slides & Cassettes
    • 7.2.3.5. Fixatives
• 7.3. Services
  • 7.3.1. Imaging Services
    • 7.3.1.1. Radiology Reading Services
    • 7.3.1.2. Advanced Imaging Quantification Services
  • 7.3.2. Pathology
• 7.4. Software & Analytics
  • 7.4.1. Imaging Analytics
  • 7.4.2. Genomic Analytics
  • 7.4.3. Pathology Informatics

8. Brain Cancer Diagnostics Market, by Tumor Type

• 8.1. Primary Brain Tumors
  • 8.1.1. Benign
    • 8.1.1.1. Chordomas
    • 8.1.1.2. Glomus Jugulare
    • 8.1.1.3. Meningiomas
    • 8.1.1.4. Pituitary Adenomas
  • 8.1.2. Malignant
    • 8.1.2.1. Medulloblastomas
    • 8.1.2.2. Astrocytomas
    • 8.1.2.3. Glioblastomas multiforme
• 8.2. Secondary Brain Tumors

9. Brain Cancer Diagnostics Market, by Sample Type

• 9.1. Tissue Samples
• 9.2. Biofluid Samples
  • 9.2.1. Blood Samples
  • 9.2.2. Cerebrospinal Fluid Samples

10. Brain Cancer Diagnostics Market, by Tumor Grade Type

• 10.1. Grade IV
• 10.2. Grade III
• 10.3. Grade II
• 10.4. Grade I

11. Brain Cancer Diagnostics Market, by Clinical Application

• 11.1. Diagnosis & Characterization
  • 11.1.1. Initial Detection
  • 11.1.2. Differential Diagnosis
  • 11.1.3. Pre-Treatment Assessment
    • 11.1.3.1. Preoperative Tumor Mapping
    • 11.1.3.2. Surgical Planning
    • 11.1.3.3. Radiation Planning
• 11.2. Molecular & Pathologic Workup
  • 11.2.1. Classification & Subtyping
  • 11.2.2. Grading & Prognosis
  • 11.2.3. Treatment Selection
• 11.3. Monitoring & Recurrence Assessment
  • 11.3.1. Response Monitoring
  • 11.3.2. Surveillance & Follow-Up
  • 11.3.3. Disease Tracking

12. Brain Cancer Diagnostics Market, by End User

• 12.1. Hospitals
• 12.2. Specialty Clinics
• 12.3. Diagnistics Laboratories
• 12.4. Academic & Research Institutes

13. Brain Cancer Diagnostics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Brain Cancer Diagnostics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Brain Cancer Diagnostics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Siemens Healthineers AG
• 17.2. GE HealthCare Technologies Inc.
• 17.3. Koninklijke Philips N.V.
• 17.4. Canon Medical Systems Corporation
• 17.5. F. Hoffmann-La Roche AG
• 17.6. Thermo Fisher Scientific, Inc.
• 17.7. Illumina, Inc.
• 17.8. Danaher Corporation
• 17.9. Bayer AG
• 17.10. Fujifilm Holdings Corporation
• 17.11. QIAGEN N.V.
• 17.12. Bracco Group
• 17.13. Shanghai United Imaging Healthcare Co., Ltd.
• 17.14. Laboratory Corporation of America Holdings
• 17.15. Guerbet Laboratories Limited
• 17.16. Caris Life Sciences
• 17.17. Brainlab SE
• 17.18. Bio-Techne Corporation
• 17.19. NeoGenomics Laboratories, Inc.
• 17.20. Carl Zeiss Meditec AG
• 17.21. Bruker Corporation
• 17.22. Hamamatsu Photonics K.K.
• 17.23. 10x Genomics, Inc.
• 17.24. Medtronic plc
• 17.25. Biocartis NV
• 17.26. Elekta AB
• 17.27. Esaote S.p.A.
• 17.28. Gencurix, Inc.
• 17.29. Henry Ford Health
• 17.30. Hitachi High-Tech Corporation
• 17.31. MDxHealth
• 17.32. NantOmics, LLC
• 17.33. Novocure GmbH
• 17.34. Oncologica Limited
• 17.35. Quanterix Corporation
• 17.36. Quibim, S.L.
• 17.37. Servier Pharmaceuticals
• 17.38. Shimadzu Corporation
• 17.39. Telix Pharmaceuticals Limited
• 17.40. Teva Pharmaceutical Industries Ltd.